Trial Information
Inclusion Criteria:
1. Proved by pathology in 60 cases of osteosarcoma patients
2. PS ≤ 2, survival period is more than 6 months
3. Normal function of liver and kidney
4. No chemotherapy contraindication, patients treat with high dose methotrexate
5. Get signed written informed consent form
6. Have a good compliance with take blood and follow-up
Exclusion Criteria:
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
blood concentration of MTX
Outcome Time Frame:
up to 3 years
Safety Issue:
Yes
Principal Investigator
Chen Wang
Investigator Role:
Study Chair
Investigator Affiliation:
Tianjin Medical University Cancer Institute and Hospital
Authority:
United States: Institutional Review Board
Study ID:
CIH-WAC-201205001
NCT ID:
NCT01758666
Start Date:
September 2012
Completion Date:
December 2014
Related Keywords:
- Osteosarcoma
- Osteosarcoma